It is known that the Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. An individual-patient-data pooled meta-analysis of 4 randomized ABSORB trials was performed to evaluate the efficacy and safety of BVS through this 3-year period. Patients with coronary artery disease were randomly allocated to receive either everolimus-eluting Absorb BVS or cobalt-chromium everolimus-eluting stents. The findings published in the Circulation journal showed that BVS was associated with increased rates of target lesion failure and device thrombosis between 1 and 3 years and cumulatively through 3 years of follow-up in comparison to everolimus-eluting stents.